Coronary artery bypass grafting in a patient with gout arthritis by Ugurlucan, Murat et al.
52 Journal of Cardiovascular Disease Research Vol. 3 / No 1
Coronary artery bypass grafting in a patient with gout arthritis
Murat Ugurlucan, Ugur Filizcan1, Ilker Murat Caglar, Ertugrul Zencirci, Erhan Kaya2, 
Mehmet Ugur Es1, Tayfun Gurol1, Yahya Yildiz2
Duzce Ataturk State Hospital, Cardiovascular Surgery Clinic, Duzce, 1Maltepe University Medical Faculty, 
Department of Cardiovascular Surgery, Istanbul, 2Pendik Bolge Hospital, Department of Cardiovascular 
Surgery, Istanbul, Turkey
Address for correspondence: Dr. Murat Ugurlucan, Bozkurt Caddesi, No: 110-112, Benli Apt., Daire: 6, 
80250 Kurtulus / Istanbul, Turkey. E-mail: muratugurlucan@yahoo.com
JCDR
INTRODUCTION
Cardiovascular disorders are one of the the leading causes 
of mortality and morbidity today all over the world. They 
are endemic, and have been seen to increasingly affect a 
considerable number of people. They are also responsible 
for a major financial burden on the community and cause 
healthcare expenses. Although ischemic heart disease can 
be seen in different age groups, usually it is a disease of the 
aging population in whom related or un-related systemic 
disorders may also co-exist. On the other hand, other than 
the well known risk factors such as genetic inheritance, 
hyperlipidemia, cigarette smoking etc, it is well known that 
some of these co-existing systemic medical problems may 
also presdispose to coronary artery disease.[1]
Gout disease is a metabolic arthritis. It is characterized 
with deposition of crystals of monosodium urate due to 
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the increased circulating levels of uric acid in the blood.[2] 
Literature includes scant reports about the co-existance of 
Gout arthritis and ischemic heart disease, or hyperuricemia 
related coronary artery disease.[1,3-13] In this report, we 
present pre-, peri-, and post-operative strategies in a 
63-year-old male patient with the history of Gout disease, 
and who underwent a successful surgical treatment for 
coronary artery disease.
CASE REPORT
The patient was a 63-year-old white Turkish male living in 
Istanbul, Turkey who presented to the clinic with increasing 
chest pain on exertion, which had progressed in the last six 
months. He was 169 cm tall and weighed 74 kg. He had been 
a smoker for more than 45 years, and on an average smoked 
1-1.5 packs per day. His family history was negative for 
cardiovascular disorders. He was not hypertensive (blood 
pressure of 128/76 mmHg on left arm and 132/77 mmHg 
on right arm at rest) and did not have diabetes mellitus 
(overnight fasting blood glucose of 98 mg/dL, normal 
range: < 100 mg/dL). Blood lipid profile indicated total 
cholesterol and low density lipoprotein levels of 193 mg/
dL (normal range: < 200 mg/dL) and 124 mg/dL (normal 
range: < 130mg/dL), respectively. Cardiologic check up 
protocol was considered and the patient underwent stress 
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electrocardiography which resulted positive. Myocardial 
thallium perfusion scintigraphy indicated ischemic zones 
at the inferior, inferolateral and inferoapical zones of the 
heart. According to the results, coronary angiography 
was performed and it revealed triple vessel disease with 
subtotal occlusion of left anterior descending artery 
(LAD) at the midportion, midportion 80% stenosis at the 
circumflex coronary artery (Cx) and 70% stenosis at the 
right coronary artery (RCA). Echocardiography was normal 
with preserved left ventricular functions (65% ejection 
fraction) and left ventricular hypertrophy. Following the 
consent of the patient, coronary artery bypass grafting 
(CABG) was planned.
During the preparatory phase for surgery, the patient 
complained of acute first toe pain. The first toe looked 
swollen, hyperemic and painful on palpation. Laboratory 
findings including complete blood count, blood lipid 
profile, renal and hepatic enzymes, clotting times, were 
normal except increased serum uric acid levels (10.74 mg/
dl, Normal: 3.4-7 mg/dl) and slighly elevated C-reactive 
protein (6.72 mg/L, Normal: 0-5 mg/L). He was consulted 
with internal medicine department and diagnosed as Gout 
arthritis. He was prescribed allopurinol 300 mg twice 
daily and scheduled for surgery when the circulating uric 
acid levels returned to normal. Following four days of 
treatment, uric acid levels returned to normal limits, and he 
underwent triple vessel CABG (Left internal mammarian 
artery to LAD, aorta-first obtuse marginal artery and aorta-
posterior descending branch of the right coronary artery 
bypasses with separate saphenous veins) with the use of 
cardiopulmonary bypass on arrested heart at 33-34°C. Cross 
clamp and cardiopulmonary bypasses were 35 minutes and 
47 minutes, respectively. After the operation, the patient was 
transferred to the intensive care unit and extubated there on 
the post-operative 4th hour. He was taken to the ward the 
next day and discharged on the 6th day. Blood and blood 
product usage was 1 units of erythrocyte suspension and 
2 units of fresh frozen plasma in total.
Immediately after the surgery, there was a slight increase 
in serum uric acid levels (7.4 mg/dl) detected in the blood 
drawn in the intensive care unit. As soon as the patient 
was extubated and oral intake was started, allopurinol was 
initiated at the same pre-operative dosage, and this returned 
the serum uric acid levels to normal. Post-operative course 
was otherwise uneventful. He has been followed symptom 
free for more than 9 months and is on allopurinol treatment 
in addition to anti-aggregant (aspirin, 100mg daily), anti-
lipidemic (atorvastatin, 20mg daily) and low dose beta-
blocker (metoprolol 25 mg daily) medications and a low 
calori diet.
DISCUSSION
Coronary artery disease is the leading cause of mortality 
and morbidity worldwide in the current decade. With 
the advances in medical knowledge about the different 
pathophysiologic events leading to ischemic heart disease, 
diagnostic methods and treatment strategies, various 
therapeutic measures are now-a-day performed to prevent, 
diagnose, treat and obtain deeper knowledge about 
the disease. It is very well known that there are certain 
risk factors such as genetic susceptibility, hypertension, 
hyperlipidemia, smoking, and diabetes mellitus, which 
may predispose an individual to coronary artery disease. 
Additionally, hyperhomocysteinemia and metabolic 
syndromes have been identified as other risk factors for 
the disease as well as predictors of the success of the 
treatment and survival of the patients.[1] Recently, elevated 
serum uric acid level is identified as an independent risk 
factor for cardiovascular diseases.[1,3-13] Several prospective 
studies have shown an association between hyperuricemia 
and cardiovascular diseases and death.[1,5-7,10,11] In our case, 
the patient only had smoking as a major cardiovarcular 
risk factor, and otherwise he was not hypertensive, 
hyperlipidemic, or diabetic, and did not define positive 
family history. We may speculate that in addition to the over 
45 years of cigarettes smoking history, increased serum 
uric acid levels might have increased the risk of coronary 
artery disease or have exacerbated the symptoms of the 
patient in our case study.
Gout is a kind of acute inflammatory arthritis, and 
characterized by recurrent painful attacks. In more 
than half of the patients, the metatarsophalangeal joint 
is the most commonly affected region as well as the 
presenting symptom of the patients in the clinic. The 
pathology is caused by the crystalization, accumulation 
and deposition of elevated levels of uric acid of 
monosorium urate character in the blood, at the joints, 
tendons, cartilages, and the surrounding tissues. This 
leads to painful attacks. Additionally, the disease may also 
present as tophi, kidney stones, or urate nephropathy.[2] 
It has been shown that chronic inflammatory disorders 
such as systemic lupus erythematosus, rheumatiod 
arthritis, ankylosing spondilitis, diabetes mellitus, etc 
are associated with shorter life expectancy in affected 
individuals as compared to the general population.[1] 
On the other hand, hyperuricemia is associated with 
reduced survival due to increased tendency to obesity, 
hypertension, insulin resistance, diuretic usage and renal 
disease.[1] The National Health and Nutrition Examination 
Survey I Follow-Up Study reported that serum uric 
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mortality in subjects above 45 years of age regardless 
of race, menopausal status, diuretic use, or presence of 
cardiovascular disease.[6] The Framingham Study showed 
that serum urate levels were not independently associated 
with the risk of coronary heart disease; however, Gout 
was associated with a 60% increased risk of coronary 
artery disease.[5] A recent study, based on the Multiple   
Risk Factor Intervention Trial reports that Gout may 
lead to upto 26% increased risk of acute myocardial   
infarction.[3] Choi et al.,[14] in their 12 years Health 
Professionals Follow-Up Study, which included 51,297 
male participants, strongly support the link between 
hyperuricemia, Gout, and cardiovascular diseases.
Although a clear mechanism indicating the consequences 
of hyperuricemia on cardiovascular diseases and decreased 
survival could not be identified, a recent novel rodent 
model showed that that uric acid could cause renal afferent 
arteriolopathy and tubulointerstitial disease, which leads 
to hypertension.[15] When the serum uric acid levels   
are reversed, the renal lesions and hypertension were 
prevented.[9,11,14] Another explanation for the increased 
cardiovascular disease rate in the presence of Gout 
may be the ongoing and relapsing inflammation due 
to hyperuricemia among patients with the disease, 
which might enhance and promote atherogenesis and 
thrombogenesis, as seen in other inflammatory rheumatic 
disorders.[11,12]
In conclusion, patients with Gout have higher risks 
of cardiovascular disorders, myocardial infarction and 
death due to increased blood uric acid levels. As sson 
as hyperuricemia has been diagnosed, strict control 
of Gout should be aimed for, to prevent any systemic 
complications[12,13] as well as cardiovascular consequences. 
This can be achieved with a multidisciplinary approach 
through the usage of well known cardioprotective 
medications such as aspirin, statins, beta-blockers when 
needed, and angiotensin converting enzyme inhibitors 
following coronary artery bypass grafting.
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